1 Pre-Specified Outcomes All primary and secondary outcomes and their components were pre-specified, i.e., they appeared in the protocol, manual of operations.

Slides:

Advertisements

Similar presentations

ALLHAT New Research Opportunities.

Advertisements

1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

Women’s Health Study: Vitamin E in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Julie E. Buring.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

Treating to New Targets Study TNT Trial Presented at The American College of Cardiology Scientific Sessions 2005 Presented by Dr. John C. LaRosa.

Did Type of Prior Antihypertensive Therapy Influence the Heart Failure Results in ALLHAT? Richard Grimm, Barry Davis, Linda Piller, Karen Margolis, Joshua.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.

Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.

Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

Clinical Outcomes with Newer Antihyperglycemic Agents

1 ATRIAL FIBRILLATION AT BASELINE AND DURING FOLLOW-UP in The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial November 9, 2003.

1 U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Major Outcomes in High Risk Hypertensive.

1 Antihypertensive Trial Outcome Differences: Diuretic vs. Calcium Channel Blocker Compared to participants assigned to the diuretic, those assigned to.

HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,

Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.

Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

1 Review of the Design and Initial Findings for Pre-specified Outcomes and Subgroups Paul K. Whelton, M.D., M.Sc. Loyola University Medical Center Maywood,

Regulatory History of Aspirin Cardiovascular and Renal Drugs Advisory Committee Meeting Michelle M. Jackson, Ph.D. Division of Over-The-Counter Drug Products.

LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.

ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:

7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.

ASCOT and Steno-2: Aggressive risk reduction benefits two different patient populations *Composite of CV death, nonfatal MI or stroke, revascularization,

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.

4S: Scandinavian Simvastatin Survival Study

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme IMAGINEIMAGINE Presented at The European Society of.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

Cardiovascular Outcomes in Hypertensives with CHD Randomized to Amlodipine versus Lisinopril in ALLHAT Frans Leenen MD, PhD, Chuke Nwachuku MA, MPH, Dr.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

Angela Aziz Donnelly April 5, 2016

Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.

From: Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study Ann Intern Med. 2015;163(5):

Clinical Outcomes with Newer Antihyperglycemic Agents

Clinical Outcomes with Newer Antihyperglycemic Agents

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Copyright © 2012 American Medical Association. All rights reserved.

The Importance of Adequately Powered Studies

Health and Human Services National Heart, Lung, and Blood Institute

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

All-cause mortality by treatment group

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

The Anglo Scandinavian Cardiac Outcomes Trial

First time a CETP inhibitor shows reduction of serious CV events

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Five Things You Need to Know About Secondary Prevention Post-ACS

Health and Human Services National Heart, Lung, and Blood Institute

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

The following slides highlight a report by Dr

Cause of death Treatment-arm events, % (n=45 054)

FIELD: Primary outcome

Cohort and Community Surveillance Components

Presentation transcript:

1 Pre-Specified Outcomes All primary and secondary outcomes and their components were pre-specified, i.e., they appeared in the protocol, manual of operations and study forms. Primary Outcome – Coronary Heart Disease (CHD) – fatal CHD or non-fatal MI Secondary Outcomes 1. All-cause death 2. Combined CHD (CHD, coronary revascularizations, or hospitalized angina) 3. Stroke ALLHAT

2 Pre-Specified Secondary Outcomes (Continued) 4. Combined Cardiovascular Disease (CHD, stroke, coronary revascularizations, heart failure [treated non- hospitalized, hospitalized, fatal], angina (treated non- hospitalized, hospitalized), peripheral arterial disease (revascularization procedure) 5. Left ventricular hypertrophy by ECG 6. Renal disease a. Slope of reciprocal of creatinine b. End-stage renal disease (dialysis or transplant) 7. Health-related quality of life; Major costs of medical care 8. Cancer 9. Gastrointestinal bleeding ALLHAT

3 Validity of Conclusions Based on Secondary Outcome Differences 1) Secondary outcomes can be validly analyzed if the primary outcome difference is not statistically significant provided that they were declared a priori and are clinically important. 2) The method to capture outcomes was the same in each treatment groups and the randomization process assures us that comparisons are unbiased. 3) Outcomes for HF & CVD are still compelling even after considering the number of comparisons made. ALLHAT